• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Duane Jon R bought $60,204 worth of shares (6,920 units at $8.70), increasing direct ownership by 6% to 121,028 units (SEC Form 4)

    3/8/24 4:05:19 PM ET
    $IRWD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IRWD alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Duane Jon R

    (Last) (First) (Middle)
    C/O IRONWOOD PHARMACEUTICALS, INC.
    100 SUMMER STREET, SUITE 2300

    (Street)
    BOSTON MA 02110

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    IRONWOOD PHARMACEUTICALS INC [ IRWD ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    03/06/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Class A Common Stock 03/06/2024 P 6,920 A $8.7 121,028 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    /s/ Brian Tessler, Attorney-in-Fact 03/08/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $IRWD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IRWD

    DatePrice TargetRatingAnalyst
    4/15/2025Overweight → Equal Weight
    Wells Fargo
    4/15/2025Buy → Hold
    Jefferies
    4/14/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    9/9/2024$5.00Market Perform
    Leerink Partners
    8/8/2024$12.00 → $4.00Overweight → Equal Weight
    CapitalOne
    1/17/2024$21.00Buy
    Craig Hallum
    12/14/2023$20.00Overweight
    Wells Fargo
    11/9/2023$21.00Buy
    Jefferies
    More analyst ratings

    $IRWD
    Financials

    Live finance-specific insights

    See more
    • Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results; Achieves 2024 Financial Guidance

      – Announced positive data from open-label extension study demonstrating an increased number of patients on apraglutide achieving enteral autonomy over time – – Initiated rolling NDA submission; on track to be completed in Q3 2025 – – LINZESS® (Iinaclotide) EUTRx prescription demand growth of 11% for full-year 2024 year-over-year – – 2024 Ironwood revenue of $351 million, GAAP net income of $2 million and adjusted EBITDA of $101 million – Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its fourth quarter and full year 2024 results

      2/27/25 7:00:00 AM ET
      $IRWD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Investor Update Call

      Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced it will host its fourth quarter and full year 2024 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, February 27, 2025. Individuals interested in participating in the call should dial (888) 596-4144 (U.S. and Canada) or (646) 968-2525 (international) using conference ID number and event passcode 2530602. To access the webcast, please visit the Investors section of Ironwood's website at www.ironwoodpharma.com. The call will be available for replay via telephone starting Thursday, February 27, 2025, at approximately 11:30 a.m. Eastern Time, running through 11:59 p.m. Eastern Time on Thursday, March

      2/20/25 4:00:00 PM ET
      $IRWD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ironwood Pharmaceuticals Initiates Apraglutide NDA Submission, Highlights Compelling New Data and Updates Corporate Structure to Position for the Future

      – Data from open label extension study of apraglutide demonstrate further increase in patients achieving enteral autonomy – – Initiated rolling NDA submission, now to include long-term extension data given continued clinical improvement over time, with submission completion expected in Q3 2025 – – Organizational restructuring positions the Company to realize the potential of apraglutide in SBS and long-term success in GI and rare disease – – Expects adjusted EBITDA excluding stock-based compensation of greater than $85 million in 2025, driven by strong LINZESS prescription demand growth and expense management to offset pricing headwinds – - Greg Martini named Chief Financial Officer

      1/29/25 4:05:00 PM ET
      $IRWD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IRWD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Ironwood Pharma downgraded by Wells Fargo

      Wells Fargo downgraded Ironwood Pharma from Overweight to Equal Weight

      4/15/25 9:27:22 AM ET
      $IRWD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ironwood Pharma downgraded by Jefferies

      Jefferies downgraded Ironwood Pharma from Buy to Hold

      4/15/25 9:27:01 AM ET
      $IRWD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ironwood Pharma downgraded by Citizens JMP

      Citizens JMP downgraded Ironwood Pharma from Mkt Outperform to Mkt Perform

      4/14/25 11:37:23 AM ET
      $IRWD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IRWD
    SEC Filings

    See more
    • Ironwood Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - IRONWOOD PHARMACEUTICALS INC (0001446847) (Filer)

      5/7/25 7:11:08 AM ET
      $IRWD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Ironwood Pharmaceuticals Inc.

      SCHEDULE 13G/A - IRONWOOD PHARMACEUTICALS INC (0001446847) (Subject)

      4/30/25 11:22:08 AM ET
      $IRWD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Ironwood Pharmaceuticals Inc.

      DEFA14A - IRONWOOD PHARMACEUTICALS INC (0001446847) (Filer)

      4/28/25 5:27:54 PM ET
      $IRWD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IRWD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Ironwood Pharmaceuticals Reports First Quarter 2025 Results

      – On track to achieve FY 2025 financial guidance; raised adjusted EBITDA guidance to greater than $105 million for 2025 – – LINZESS® (linaclotide) EUTRx prescription demand growth of 8% year-over-year; in line with full-year expectations – – Exploring strategic alternatives to maximize stockholder value – Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its first quarter 2025 results and recent business performance. "LINZESS demand continues to be strong, and we remain on track to meet our full-year 2025 guidance and further, recently

      5/7/25 7:05:00 AM ET
      $IRWD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference

      Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced that management will participate in a fireside chat at The Citizens Life Sciences Conference on Wednesday, May 7th at 12:00 p.m. ET at the New York Hilton Midtown. A live webcast of Ironwood's fireside chat will be accessible through the Investors section of the company's website at www.ironwoodpharma.com. A replay of the webcast will be available on Ironwood's website following the conference. About Ironwood Pharmaceuticals Ironwood Pharmaceuticals (NASDAQ:IRWD) is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases. Ironwood is advancing

      4/30/25 4:25:00 PM ET
      $IRWD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance

      – Reiterates 2025 guidance of LINZESS U.S. net sales of $800-$850 million and total Ironwood revenue of $260-290 million – – LINZESS (Iinaclotide) EUTRx prescription demand growth in Q1 2025 of 8% year-over-year; in line with full-year expectations - – Raises adjusted EBITDA to greater than $105 million for 2025 – Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced it reiterates its full year 2025 LINZESS U.S. net sales and total Ironwood revenue guidance and raises its adjusted EBITDA guidance. Ironwood plans to report full first quarte

      4/25/25 7:05:00 AM ET
      $IRWD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IRWD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Ironwood Pharmaceuticals Inc.

      SC 13G - IRONWOOD PHARMACEUTICALS INC (0001446847) (Subject)

      11/14/24 3:31:33 PM ET
      $IRWD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Ironwood Pharmaceuticals Inc.

      SC 13G/A - IRONWOOD PHARMACEUTICALS INC (0001446847) (Subject)

      11/12/24 3:47:50 PM ET
      $IRWD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Ironwood Pharmaceuticals Inc.

      SC 13G/A - IRONWOOD PHARMACEUTICALS INC (0001446847) (Subject)

      11/4/24 11:46:39 AM ET
      $IRWD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IRWD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Denner Alexander J was granted 10,416 shares, increasing direct ownership by 7% to 166,769 units (SEC Form 4)

      4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)

      4/4/25 4:05:07 PM ET
      $IRWD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Gaskins Tammi L claimed ownership of 245,159 shares (SEC Form 3)

      3 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)

      3/21/25 4:05:05 PM ET
      $IRWD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Mccourt Thomas A sold $244,753 worth of shares (139,064 units at $1.76), decreasing direct ownership by 11% to 1,160,634 units (SEC Form 4)

      4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)

      2/12/25 9:00:11 PM ET
      $IRWD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IRWD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Duane Jon R bought $60,204 worth of shares (6,920 units at $8.70), increasing direct ownership by 6% to 121,028 units (SEC Form 4)

      4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)

      3/8/24 4:05:19 PM ET
      $IRWD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Emany Sravan Kumar bought $100,216 worth of shares (10,684 units at $9.38), increasing direct ownership by 4% to 301,733 units (SEC Form 4)

      4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)

      3/6/24 4:05:12 PM ET
      $IRWD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Emany Sravan Kumar bought $300,119 worth of shares (36,072 units at $8.32), increasing direct ownership by 24% to 188,730 units

      4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)

      9/18/23 5:07:12 PM ET
      $IRWD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IRWD
    Leadership Updates

    Live Leadership Updates

    See more
    • Millrose Properties Set to Join S&P SmallCap 600

      NEW YORK, Feb. 5, 2025 /PRNewswire/ -- Millrose Properties Inc. (NYSE:MRP) will replace Ironwood Pharmaceuticals Inc. (NASD: IRWD) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, February 10. S&P 500 constituent Lennar Corp (NYSE:LEN) is spinning off Millrose Properties in a transaction expected to be completed on Friday, February 7. Following the spin-off, Lennar will remain in the S&P 500, and Millrose Properties, which is more representative of the small cap market space, will be added to the S&P SmallCap 600. Ironwood Pharmaceuticals is no longer representative of the small-cap market space. Following is a summary of the changes that will take place prior to

      2/5/25 6:28:00 PM ET
      $IRWD
      $LEN
      $SPGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Homebuilding
      Consumer Discretionary
    • Memo Therapeutics AG appoints Paul Carter as Chairperson

      PRESS RELEASE Memo Therapeutics AG appoints Paul Carter as Chairperson Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV Extensive public and private market experience following executive positions in numerous biopharma companies                  Schlieren / Zurich, Switzerland, 8 July, 2024 – Memo Therapeutics AG (or "MTx"), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces the appointment of Paul Carter as Chairperson of the Board of Directors. Paul has had an extensive executive career in the biopharma space, with commercial a

      7/8/24 7:00:00 AM ET
      $IMTX
      $IRWD
      $VECT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Ironwood Pharmaceuticals Appoints Sravan K. Emany as Chief Financial Officer

      Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a GI-focused healthcare company, today announced the appointment of Sravan K. Emany as senior vice president, chief financial officer. Mr. Emany will become a member of Ironwood's Leadership Team and be responsible for all financial operations of the company, including financial planning and reporting, tax, accounting, and investor relations effective December 6, 2021. He will report to Thomas McCourt, chief executive officer of Ironwood. Mr. McCourt commented, "We always look to our mission to guide our efforts to deliver the highest value to our stakeholders. We believe Sravan's deep financial and corporate strategy capabilities within the he

      12/1/21 7:30:00 AM ET
      $IRWD
      Biotechnology: Pharmaceutical Preparations
      Health Care